References
- Vogelzang NJ, Breitbart W Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripartite assessment survey. Semin Hematol. 1997;34:4–12
- Curt GA, Breitbart W Cella D, et al. Impact of cancer-related fatigue on the lives of patients: New findings from the fatigue coalition. Oncologist 2000 5:353–60
- Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol. 1998;25\(suppl 7):43–6
- Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218–34
- Demetri GD, Kris M, Wade J, et al. Quality-of-life benefits in chemotherapy patients treated with epoetin alfa are independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol. 1998;16:3412–25
- Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113:172–9
- Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34 (suppl 2):13–19
- Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms of cancer with the functional assessment of cancer therapy (FACT) measurement system. J Pain Sympt Manage. 1997;13:63–74
- Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–74
- Kazis LE, Andersen JJ, Meenan RF. Effect sizes for interpreting changes in health studies. Med Care. 1989;27:S178–S189